ArticleRheumatology international2017

Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.

C Tzanetakos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.